EirGenix, Inc products

Product Pipeline

Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: Preclinical.

Product: EG12021 Bevacizumab Biosimilar. Indication: Cancer. Target: VEGF. Status: Preclinical.

Product: EG62054 Biosimilar. Indication: Undisclosed. Target: Undisclosed. Status: Preclinical.

Product: EG74032 CRM197 Carrier Protein. Target: Carrier protein for conjugate vaccines. Status: GMP manufacturing.

Product: New Formulation. Indication: Cancer. Target: HER2. Status: Preclinical.